Annual Cash & Cash Equivalents
$67.60 M
+$22.45 M+49.70%
December 31, 2023
Summary
- As of February 7, 2025, TRDA annual cash & cash equivalents is $67.60 million, with the most recent change of +$22.45 million (+49.70%) on December 31, 2023.
- During the last 3 years, TRDA annual cash & cash equivalents has risen by +$28.56 million (+73.14%).
- TRDA annual cash & cash equivalents is now -76.77% below its all-time high of $291.06 million, reached on December 31, 2021.
Performance
TRDA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$78.05 M
-$107.20 M-57.87%
September 30, 2024
Summary
- As of February 7, 2025, TRDA quarterly cash and cash equivalents is $78.05 million, with the most recent change of -$107.20 million (-57.87%) on September 30, 2024.
- Over the past year, TRDA quarterly cash and cash equivalents has increased by +$26.17 million (+50.44%).
- TRDA quarterly cash and cash equivalents is now -73.18% below its all-time high of $291.06 million, reached on December 31, 2021.
Performance
TRDA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TRDA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +49.7% | +50.4% |
| 3 y3 years | +73.1% | +72.8% |
| 5 y5 years | +301.3% | +72.8% |
TRDA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -76.8% | +49.7% | -73.2% | +72.8% |
| 5 y | 5-year | -76.8% | +301.3% | -73.2% | +99.9% |
| alltime | all time | -76.8% | +301.3% | -73.2% | +99.9% |
Entrada Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $78.05 M(-57.9%) |
| Jun 2024 | - | $185.25 M(+170.7%) |
| Mar 2024 | - | $68.44 M(+1.2%) |
| Dec 2023 | $67.60 M(+49.7%) | $67.60 M(+30.3%) |
| Sep 2023 | - | $51.88 M(-34.9%) |
| Jun 2023 | - | $79.74 M(-65.0%) |
| Mar 2023 | - | $227.65 M(+404.1%) |
| Dec 2022 | $45.16 M | $45.16 M(-15.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $53.31 M(-41.3%) |
| Jun 2022 | - | $90.87 M(+7.4%) |
| Mar 2022 | - | $84.64 M(-70.9%) |
| Dec 2021 | $291.06 M(+645.5%) | $291.06 M(+138.2%) |
| Sep 2021 | - | $122.17 M(-10.8%) |
| Jun 2021 | - | $136.95 M(+250.7%) |
| Dec 2020 | $39.05 M(+131.8%) | $39.05 M |
| Dec 2019 | $16.84 M | - |
FAQ
- What is Entrada Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Entrada Therapeutics?
- What is Entrada Therapeutics annual cash & cash equivalents year-on-year change?
- What is Entrada Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Entrada Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of TRDA is $67.60 M
What is the all time high annual cash & cash equivalents for Entrada Therapeutics?
Entrada Therapeutics all-time high annual cash & cash equivalents is $291.06 M
What is Entrada Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, TRDA annual cash & cash equivalents has changed by +$22.45 M (+49.70%)
What is Entrada Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TRDA is $78.05 M
What is the all time high quarterly cash and cash equivalents for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly cash and cash equivalents is $291.06 M
What is Entrada Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, TRDA quarterly cash and cash equivalents has changed by +$26.17 M (+50.44%)